The FDA has released the full Director's Summary for the Glas G2 marketing authorization, and the science tells a compelling story.

At the center of the authorization is a three-month randomized actual use study that ARAC designed and executed. The study enrolled adults 22–64 who smoked more than 10 cigarettes daily and were open to trying ENDS. The results were significant:

Complete switching rates of 12–18% across all five flavors, more than double the rate seen in smokers attempting to quit with no support. Nearly half of participants reduced their cigarette consumption by 50–99%.

The FDA cited these findings as central to its conclusion that the benefits of the Glas G2 products outweigh the risks to the population as a whole, the APPH standard that every PMTA must meet.

This is what rigorous behavioral science looks like in practice. We are proud to have supported Glas in building the evidentiary foundation that made this authorization possible.

Full summary linked here.